A detailed history of Trexquant Investment LP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 11,500 shares of ALDX stock, worth $58,189. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,500
Holding current value
$58,189
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.19 - $6.32 $36,685 - $72,680
11,500 New
11,500 $61,000
Q3 2023

Nov 13, 2023

SELL
$6.11 - $8.16 $24,073 - $32,150
-3,940 Reduced 25.3%
11,631 $77,000
Q2 2023

Aug 11, 2023

SELL
$7.11 - $11.89 $496,007 - $829,470
-69,762 Reduced 81.75%
15,571 $130,000
Q1 2023

May 15, 2023

BUY
$5.77 - $9.93 $184,766 - $317,978
32,022 Added 60.07%
85,333 $847,000
Q4 2022

Feb 13, 2023

BUY
$5.08 - $7.09 $170,870 - $238,479
33,636 Added 170.96%
53,311 $371,000
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $74,765 - $152,284
19,675 New
19,675 $105,000
Q3 2021

Nov 12, 2021

SELL
$7.94 - $11.31 $92,858 - $132,270
-11,695 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$10.44 - $14.85 $122,095 - $173,670
11,695 New
11,695 $133,000
Q1 2020

May 08, 2020

SELL
$1.62 - $6.4 $19,932 - $78,745
-12,304 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$4.73 - $7.98 $58,197 - $98,185
12,304 New
12,304 $71,000
Q2 2019

Aug 09, 2019

SELL
$6.0 - $9.0 $140,442 - $210,663
-23,407 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$7.14 - $9.85 $167,125 - $230,558
23,407 New
23,407 $211,000
Q4 2018

Feb 13, 2019

SELL
$7.26 - $13.29 $281,223 - $514,801
-38,736 Closed
0 $0
Q3 2018

Nov 09, 2018

BUY
$6.8 - $14.35 $263,404 - $555,861
38,736 New
38,736 $535,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $295M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.